Singapore markets close in 2 hours 57 minutes

Straits Times Index
3,196.92
+42.23(+1.34%)
Nikkei
38,142.27
+180.47(+0.48%)
Hang Seng
16,422.84
+171.00(+1.05%)
FTSE 100
7,847.99
+27.63(+0.35%)
Bitcoin USD
61,254.21
-2,616.93(-4.10%)
CMC Crypto 200
885.54
0.00(0.00%)

Cassava Sciences, Inc. (SAVA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD

Add to watchlist

21.27

+0.24

(+1.14%)

At close: 04:00PM EDT

21.28

+0.01

(+0.05%)

After hours:

06:45PM EDT

Trade prices are not sourced from all markets

All

GlobeNewswire
Redemption Date Announced for Warrants
Monday, May 6, 2024 is Last and Final Day to Exercise Warrants.Once Redeemed, the Warrants Will Cease to Exist and Have No Value. AUSTIN, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (“Cassava Sciences” or the "Company") today announced that Monday, May 6, 2024 is the last and final day to exercise the warrants that were previously distributed to its shareholders on January 3, 2024 (the “Warrants”). Holders who exercise their Warrants will receive 1.5 shares of
GlobeNewswire
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials Continue as Planned, Without Modification. Final Clinical Safety Data for Simufilam Are Expected at the Conclusion of the Phase 3 Program. AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced th
Simply Wall St.
Bullish Cassava Sciences Insiders Loaded Up On US$3.12m Of Stock
Quite a few insiders have dramatically grown their holdings in Cassava Sciences, Inc. ( NASDAQ:SAVA ) over the past 12...